智通财经APP获悉，8月26日，礼邦医药(09637)上市后首份中期业绩交出亮眼答卷：收入规模增至去年同期的8.6倍。更值得关注的是，这份成绩单恰逢全球肾病创新药加速商业化、优质资产持续获得资本重估，礼邦所代表的中国垂直专科Biopharma路径也由此逐渐清晰。 美国肾病专科药企Travere Therapeutics同期披露的2026年二季度财报显示，核心产品FILSPARI单季美国净销售额达1 ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several ...
Cytokinetics booked its first full quarter of MYQORZO sales on Aug. 6. Armistice Capital used the same three months to raise ...
The Nomura Small Cap Core Fund trailed its benchmark in Q2 2026 despite an exceptionally strong rally in small-cap stocks. Read the full analysis for more details.
미국 트럼프 행정부가 대형 제약사에 이어 중견 제약·바이오 기업들과 새로운 최혜국 대우(Most Favored Nation, MFN) 의약품 가격 협약을 추진한다. 28일 한국바이오협회 바이오경제연구센터 이슈브리핑에 따르면, ...
值得注意的是，截至招股意向书签署日，信诺维已有多条在履行中的创新药管线对外授权合作或转让，合作方包括Astellas PharmaInc.（以下简称“安斯泰来”）、Everest Medicines（Singapore）Pte.Ltd.（以下简称“云顶新耀”）等，相关协议潜在收款金额（包括首付款、里程碑付款等）累计超过20亿美元。
<백악관> © 나무위키 미국 백악관이 중견 제약사와 다음주 MFN 약가 협약을 발표한다. 블룸버그 통신은 트럼프 행정부가 여러 중견 바이오제약 회사들과 새로운 최혜국 대우(MFN) 의약품 ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eloxx Pharmaceuticals , Cingulate Inc and Agilon Health . 55% Off TipRanks. Unlock powerful inves ...
早期管线依托公司三大成熟技术平台（小分子靶向药物开发平台、复杂抗体药物开发平台、靶向蛋白降解药物开发平台）持续产出，覆盖抗肿瘤、抗感染、代谢、自免等多个领域，随着临床推进，后续可逐步补充公司后期管线梯队，部分高潜力管线还可通过BD交易实现价值兑现，保障公司管线的长期可持续性。
胃癌是信诺维重点布局的方向之一。据西南证券发布的胃癌专题研究报告，Claudin18.2已成为近年最大增量赛道，单抗、多款ADC及全球首款实体瘤CAR-T陆续获批或申报上市，独立构建起HER2阴性一线靶向体系，靶点BD交易频繁、商业化空间广阔。报告引 ...
针对抗感染领域，信诺维研发的注射用亚胺西福药品上市许可申请（NDA）已于2025年7月获得受理，预计于2026年获批上市。该药物为β-内酰胺酶抑制剂，抗菌谱广，可有效覆盖三大碳青霉烯耐药革兰阴性菌。针对抗肿瘤领域，公司研发的XNW5004、XNW27 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results